Phase 2RecruitingAge-related condition

A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure (GOAL-HF2)

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of 2 Dose Levels of the Oral Ghrelin Receptor Agonist AC01 Over 12 Weeks in Patients With Chronic Advanced Heart Failure With Reduced Ejection Fraction (HFrEF)

Sponsor
AnaCardio AB (Industry)
Enrollment
400 planned
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
AC01; Placebo
Ages
adults, older adults
Registry
NCT07584967, CTIS2025-524469-25-00

Full record on ClinicalTrials.gov

From the registry

The primary purpose of the study is to evaluate the safety and efficacy of 2 doses of AC01 compared to placebo over 12 weeks in participants with chronic advanced HFrEF.

Primary outcomes

  • Absolute Change from Baseline in Composite Echocardiography Z-Score at Week 12

History

  1. Study completion expected

  2. Primary completion expected

  3. Started

  4. Now recruiting

    , from Not yet recruiting to Recruiting

  5. Last registry update

  6. Registered